[177Lu]Lu-DOTATATE在不同原发部位转移性神经内分泌肿瘤中的疗效:SEPTRALU研究数据
SEPTRALU研究纳入24个中心、522例生长抑素受体过表达的晚期神经内分泌肿瘤患者,方案为每8周静脉给予177Lu-DOTATATE 7.4 GBq、共4个周期。最佳RECIST 1.1疗效为完全缓解0.7%、部分缓解33.2%、疾病稳定52.1%、肿瘤进展14%,各部位亚型均获益;中位无进展生存期以中肠最长(31.3个月),支气管肺最短(17.6个月)。研究认为该治疗在广泛部位NEN中有效且安全性好。
要点
- 中位PFS:中肠31.3个月、PPGL 30.6个月、胰腺19.8个月、支气管肺17.6个月。
- 各部位亚型均观察到获益,严重毒性少见。
核心结论
- 本研究证实177Lu-DOTATATE在多种表达SSTR的NEN中有效且安全,不受原发部位限制,胰腺NEN与其他非中肠GEP及NGEP亚型的生存结局相近。
研究设计与样本
- 多中心研究,纳入24个中心经功能影像证实SSTR过表达、任何分级或部位的晚期NEN患者,方案为每8周静脉给予177Lu-DOTATATE 7.4 GBq、共4个周期(NCT04949282),样本522例。
主要发现
- 最佳RECIST 1.1疗效:完全缓解0.7%,部分缓解33.2%,疾病稳定52.1%,肿瘤进展14%。
- 中位PFS:中肠31.3个月(95%CI 25.7-未达到),PPGL 30.6个月(14.4-未达到)。
- 中位PFS:其他GEP 24.3个月(18.0-未达到),其他NGEP 20.5个月(11.8-未达到)。
- 中位PFS:胰腺NEN 19.8个月(16.8-28.1),支气管肺NEN 17.6个月(14.4-33.1)。
- 疗效受肿瘤亚型影响,但所有分层均获益,177Lu-DOTATATE严重毒性少见。
关键数值与推荐
- 纳入标准为功能影像显示生长抑素受体过表达的晚期NEN,任何分级或部位。
- 治疗方案为177Lu-DOTATATE 7.4 GBq静脉给药,每8周一次,共4个周期(NCT04949282)。
- 疗效按RECIST 1.1评价:完全缓解0.7%、部分缓解33.2%、疾病稳定52.1%、肿瘤进展14%。
临床怎么用
- 原文结论认为177Lu-DOTATATE在广泛部位的表达SSTR的NEN中有效且安全,各部位亚型均有临床获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [177Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables. Advanced NENs overexpressing somatostatin receptors (SSTRs) on functional imaging, of any grade or location, treated at 24 centers were enrolled. The protocol consisted of four cycles of 177Lu-DOTATATE 7.4 GBq iv every 8 weeks (NCT04949282). RESULTS: The sample comprised 522 subjects with pancreatic (35%), midgut (28%), bronchopulmonary (11%), pheochromocytoma/ paraganglioma (PPGL) (6%), other gastroenteropancreatic (GEP) (11%), and other non-gastroenteropancreatic (NGEP) (9%) NENs. The best RECIST 1.1 responses were complete response, 0.7%; partial response, 33.2%; stable disease, 52.1%; and tumor progression, 14%, with activity conditioned by the tumor subtype, but with benefit in all strata. Median progression-free survival (PFS) was 31.3 months (95% CI, 25.7-not reached [NR]) in midgut, 30.6 months (14.4-NR) in PPGL, 24.3 months (18.0-NR) in other GEP, 20.5 months (11.8-NR) in other NGEP, 19.8 months (16.8-28.1) in pancreatic, and 17.6 months (14.4-33.1) in bronchopulmonary NENs. [177Lu]Lu-DOTATATE exhibited scant severe toxicity. CONCLUSION: This study confirms the efficacy and safety of [177Lu]Lu-DOTATATE in a wide range of SSTR-expressing NENs, regardless of location, with clinical benefit and superimposable survival outcomes between pNENs and other GEP and NGEP tumor subtypes different from midgut NENs.
引用
- Mitjavila M, Jimenez-Fonseca P, Belló P, et al. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023. PMID: 36877234. doi:10.1007/s00259-023-06166-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。